Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study

Sven Mahner, Julia Jueckstock, Felix Hilpert, Petra Neuser, Philipp Harter, Nikolaus de Gregorio, Annette Hasenburg, Jalid Sehouli, Annika Habermann, Peter Hillemanns, Sophie Fuerst, Hans-Georg Strauss, Klaus Baumann, Falk Thiel, Alexander Mustea, Werner Meier, Andreas du Bois, Lis-Femke Griebel, Linn Woelber, AGO-CaRE 1 investigators, Sven Mahner, Julia Jueckstock, Felix Hilpert, Petra Neuser, Philipp Harter, Nikolaus de Gregorio, Annette Hasenburg, Jalid Sehouli, Annika Habermann, Peter Hillemanns, Sophie Fuerst, Hans-Georg Strauss, Klaus Baumann, Falk Thiel, Alexander Mustea, Werner Meier, Andreas du Bois, Lis-Femke Griebel, Linn Woelber, AGO-CaRE 1 investigators

Abstract

Background: Women with node-positive vulvar cancer have a high risk for disease recurrence. Indication criteria for adjuvant radiotherapy are controversial. This study was designed to further understand the role of adjuvant therapy in node-positive disease.

Methods: Patients with primary squamous-cell vulvar cancer treated at 29 gynecologic cancer centers in Germany from 1998 through 2008 were included in this retrospective exploratory multicenter cohort study. Of 1618 documented patients, 1249 had surgical groin staging and known lymph node status and were further analyzed. All statistical tests were two-sided.

Results: Four hundred forty-seven of 1249 patients (35.8%) had lymph node metastases (N+). The majority of N+ patients had one (172 [38.5%]) or two (102 [22.8%]) positive nodes. The three-year progression-free survival (PFS) rate of N+ patients was 35.2%, and the overall survival (OS) rate 56.2% compared with 75.2% and 90.2% in node-negative patients (N-). Two hundred forty-four (54.6%) N+ patients had adjuvant therapy, of which 183 (40.9%) had radiotherapy directed at the groins (+/-other fields). Three-year PFS and OS rates in these patients were better compared with N+ patients without adjuvant treatment (PFS: 39.6% vs 25.9%, hazard ratio [HR] = 0.67, 95% confidence interval [CI[= 0.51 to 0.88, P = .004; OS: 57.7% vs 51.4%, HR = 0.79, 95% CI = 0.56 to 1.11, P = .17). This effect was statistically significant in multivariable analysis adjusted for age, Eastern Cooperative Oncology Group, Union internationale contre le cancer stage, grade, invasion depth, and number of positive nodes (PFS: HR = 0.58, 95% CI = 0.43 to 0.78, P < .001; OS: HR = 0.63, 95% CI = 0.43 to 0.91, P = .01).

Conclusion: This large multicenter study in vulvar cancer observed that adjuvant radiotherapy was associated with improved prognosis in node-positive patients and will hopefully help to overcome concerns regarding adjuvant treatment. However, outcome after adjuvant radiotherapy remains poor compared with node-negative patients. Adjuvant chemoradiation could be a possible strategy to improve therapy because it is superior to radiotherapy alone in other squamous cell carcinomas.

© The Author 2014. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
Patient characteristics and treatment diagram. CT = chemotherapy; LN = lymph node; Tx = therapy; RT = radiotherapy; RCT = radiochemotherapy.
Figure 2.
Figure 2.
Lymph node status and outcome. A) Progression-free survival. B) overall survival. P values were calculated using the two-sided log-rank test. CI = confidence interval; HR = hazard ratio; N- = node-negative; N+ = node-positive; OS = overall survival; PFS = progression-free survival.
Figure 3.
Figure 3.
Progression-free survival (A) and overall survival of (B) node-positive patients with regard to adjuvant radiotherapy to the groins +/-pelvis +/-vulva. P values were calculated using the two-sided log-rank test. CI = confidence interval; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; Tx = therapy.
Figure 4.
Figure 4.
Forest plot of progression-free survival in nodal subgroups with regard to adjuvant radiotherapy to the groins +/-pelvis +/-vulva. Results unadjusted (A) and confounder-adjusted by inverse probability of treatment weighting (B). P values were calculated using the two-sided log-rank test. CI = confidence interval; HR = hazard ratio; LN = lymph node; PFS = progression-free survival.

References

    1. Beller U, Quinn MA, Benedet JL, et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S7–S27.
    1. Hampl M, Deckers-Figiel S, Hampl JA, Rein D, Bender HG. New aspects of vulvar cancer: changes in localization and age of onset. Gynecol Oncol. 2008;109(3):340–345.
    1. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107(5):1018–1022.
    1. Gadducci A, Cionini L, Romanini A, Fanucchi A, AR G. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol/Hematol. 2006;60(3):227–241.
    1. Woelber L, Mahner S, Voelker K, et al. Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res. 2009;29(2):545–552.
    1. Woelber L, Eulenburg C, Choschzick M, et al. Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer. 2012;22(3):503–508.
    1. Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. 1986;68(6):733–740.
    1. Parthasarathy A, Cheung MK, Osann K, et al. The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol. 2006;103(3):1095–1099.
    1. Woelber L, Kock L, Gieseking F, et al. Clinical management of primary vulvar cancer. Eur J Cancer. 2011;47(15):2315–2321.
    1. Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol. 2009;114(3):537–546.
    1. Oonk MH, de Hullu JA, van der Zee AG. Current controversies in the management of patients with early-stage vulvar cancer. Curr Opin Oncol. 2010;22(5):481–486.
    1. AGO Kommission Vulva Vagina. Interdisziplinäre S2k Leitlinie für die Diagnostik und Therapie des Vulvakarzinoms und seiner Vorstufen. München: W. Zuckschwerdt Verlag; 2009.
    1. Royal College of Obstetricians and Gynaecologists: Guidelines for the Diagnosis and Management of Vulval Carcinoma, 2014. .
    1. American Joint Committee on Cancer. AJCC Cancer Staging Manual In. 6th ed., 2002. .
    1. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012;18(8):2301–2308.
    1. Wolbers M, Koller MT, Stel VS, et al. Competing risks analyses: objectives and approaches. Eur Heart J. 2014;35(42):2936–2941.
    1. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399–424.
    1. Crowson CS, Schenck LA, Green AB, Atkinson EJ, Therneau T. The Basics of Propensity Scoring and Marginal Structural Models. Department of Health Sciences Research, Mayo Clinic Rochester, Minnesota;. In: Department of Health Sciences Research, Mayo Clinic Rochester, Minnesota, 2013.
    1. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
    1. Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol. 1983;61(4):408–412.
    1. Klemm P, Marnitz S, Kohler C, Braig U, Schneider A. Clinical implication of laparoscopic pelvic lymphadenectomy in patients with vulvar cancer and positive groin nodes. Gynecol Oncol. 2005;99(1):101–105.
    1. Oonk MH, van Hemel BM, Hollema H, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol. 2010;11(7):646–652.
    1. Fons G, Groenen SMA, Oonk MHM, et al. Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. Gynecol Oncol. 2009;114(2):343–345.
    1. Origoni M, Sideri M, Garsia S, Carinelli SG, Ferrari AG. Prognostic value of pathological patterns of lymph node positivity in squamous cell carcinoma of the vulva stage III and IVA FIGO. Gynecol Oncol. 1992;45(3):313–316.
    1. van der Velden J, van Lindert AC, Lammes FB, et al. Extracapsular growth of lymph node metastases in squamous cell carcinoma of the vulva. The impact on recurrence and survival. Cancer. 1995;75(12):2885–2890.
    1. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997;90(3):448–452.
    1. Han SC, Kim DH, Higgins SA, Carcangiu ML, BM K. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiation Oncol Biol Phys. 2000;47(5):1235–1244.
    1. Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012;124(3):529–533.
    1. Moore DH, Thomas GM, Montana GS, Saxer A, Gallup DG, Olt G. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiation Oncol Biol Phys. 1998;42(1):79–85.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa